Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B.

J Clin Oncol. 2010 Nov 1;28(31):4740-6. doi: 10.1200/JCO.2010.29.2813.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.

Hess G, Smith SM, Berkenblit A, Coiffier B.

Semin Oncol. 2009 Dec;36 Suppl 3:S37-45. doi: 10.1053/j.seminoncol.2009.10.012. Review.

PMID:
19963099
4.

Temsirolimus for the treatment of mantle cell lymphoma.

Hess G.

Expert Rev Hematol. 2009 Dec;2(6):631-40. doi: 10.1586/ehm.09.57. Review.

PMID:
21082954
5.

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Keating GM.

Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Review.

PMID:
20614951
6.

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.

Coiffier B, Ribrag V.

Leuk Lymphoma. 2009 Dec;50(12):1916-30. doi: 10.3109/10428190903207548. Review.

PMID:
19757306
7.

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Hainsworth JD.

Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15. Review.

PMID:
12652459
8.

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.

Vidal L, Gafter-Gvili A, Gurion R, Raanani P, Dreyling M, Shpilberg O.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009045. doi: 10.1002/14651858.CD009045.pub2. Review.

PMID:
22972131
9.

Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.

PMID:
21530769
10.

Ofatumumab in the treatment of non-Hodgkin's lymphomas.

Karlin L, Coiffier B.

Expert Opin Biol Ther. 2015 Jul;15(7):1085-91. doi: 10.1517/14712598.2015.1055241. Review.

PMID:
26043777
11.

Temsirolimus.

Stock C, Zaccagnini M, Schulze M, Teber D, Rassweiler JJ.

Recent Results Cancer Res. 2010;184:189-97. doi: 10.1007/978-3-642-01222-8_13. Review.

PMID:
20072839
12.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Review.

PMID:
12042984
13.

Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.

Tobinai K.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S90-6. Review.

PMID:
12819934
14.

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS.

Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Review.

15.

Everolimus in diffuse large B-cell lymphomas.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Future Oncol. 2015;11(3):373-83. doi: 10.2217/fon.14.264. Review.

PMID:
25675120
16.

Signal transduction inhibitor therapy for lymphoma.

Witzig TE, Gupta M.

Hematology Am Soc Hematol Educ Program. 2010;2010:265-70. doi: 10.1182/asheducation-2010.1.265. Review.

17.

B-cell receptor pathway modulators in NHL.

Blum KA.

Hematology Am Soc Hematol Educ Program. 2015;2015:82-91. doi: 10.1182/asheducation-2015.1.82. Review.

18.

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Teachey DT, Grupp SA, Brown VI.

Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Review.

19.

Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.

Sujobert P, Rioufol C, Salles GA.

Cancer J. 2016 Jan-Feb;22(1):12-6. doi: 10.1097/PPO.0000000000000167. Review.

PMID:
26841011
20.

Novel agents in mantle cell lymphoma.

Noel MS, Friedberg JW, Barr PM.

Best Pract Res Clin Haematol. 2012 Jun;25(2):191-200. doi: 10.1016/j.beha.2012.04.001. Review.

Items per page

Supplemental Content

Support Center